CD274 and meningioma: Giles et al. proved that the combination of PP2A inhibitors and PD-L1 antibodies can promote immune-mediated antitumor activity and effectively kill meningiomas through antibody-dependent cell-mediated cytotoxicity (ADCC) [34].